Spots Global Cancer Trial Database for pharmacogenomic studies

Every month we try and update this database with for pharmacogenomic studies cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
A Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS)	NCT01824836	Estrogen Recept... Musculoskeletal... Progesterone Re... Recurrent Breas... Stage IA Breast... Stage IB Breast... Stage II Breast... Stage IIIA Brea... Stage IIIB Brea... Stage IIIC Brea...	anastrozole questionnaire a... laboratory biom... pharmacogenomic...	18 Years -	Eastern Cooperative Oncology Group
BMS-247550 in Treating Patients With Stage IV Melanoma	NCT00036764	Recurrent Melan... Stage IV Melano...	ixabepilone pharmacogenomic... laboratory biom...	18 Years -	National Cancer Institute (NCI)
ABT-888, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme	NCT00770471	Brain and Centr...	temozolomide veliparib DNA methylation... gene expression... mutation analys... proteomic profi... high performanc... immunoenzyme te... laboratory biom... mass spectromet... pharmacogenomic... pharmacological... adjuvant therap... radiation thera...	18 Years - 120 Years	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Cyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic Syndrome	NCT00445744	Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Childhood Acute... Childhood Myelo... de Novo Myelody... Essential Throm... Myelodysplastic... Polycythemia Ve... Previously Trea... Primary Myelofi... Recurrent Adult... Recurrent Child... Secondary Acute... Secondary Myelo... Secondary Myelo... Untreated Adult... Untreated Child...	cyclophosphamid... busulfan tacrolimus methotrexate cytogenetic ana... flow cytometry pharmacological... pharmacogenomic... peripheral bloo... allogeneic hema...	- 65 Years	Fred Hutchinson Cancer Center
Pazopanib Hydrochloride or a Placebo in Treating Patients With Non-Small Cell Lung Cancer Who Have Received First-Line Chemotherapy	NCT01208064	Lung Cancer	pazopanib hydro... laboratory biom... pharmacogenomic... pharmacological... quality-of-life...	18 Years - 120 Years	European Organisation for Research and Treatment of Cancer - EORTC
Study of Gemtuzumab Ozogamicin Therapy in DNA Samples From Patients With Acute Myeloid Leukemia Treated on COG-AAML0531	NCT01407757	Leukemia	DNA analysis gene expression... laboratory biom... pharmacogenomic...	- 29 Years	Children's Oncology Group
BMS-247550 in Treating Patients With Stage IV Melanoma	NCT00036764	Recurrent Melan... Stage IV Melano...	ixabepilone pharmacogenomic... laboratory biom...	18 Years -	National Cancer Institute (NCI)
Study of Blood Samples From High-Risk Postmenopausal Women Who Received Treatment on Breast Cancer Prevention Clinical Trials NSABP-P-1 or NSABP-P-2	NCT00967239	Breast Cancer	DNA analysis polymorphism an... laboratory biom... pharmacogenomic...	35 Years -	NSABP Foundation Inc
Studying Genes in Samples From Younger Patients With Desmoplastic Small Round Cell Tumor Registered on COG-D9902 or COG-ABTR01B1	NCT01430637	Sarcoma	DNA analysis RNA analysis gene expression... mutation analys... nucleic acid se... polymerase chai... laboratory biom... pharmacogenomic...	- 50 Years	Children's Oncology Group
Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Measuring Effects of Pazopanib Hydrochloride in Patients With Metastatic Kidney Cancer	NCT01599832	Clear Cell Rena... Recurrent Renal... Stage IV Renal ...	pazopanib hydro... laboratory biom... dynamic contras... pharmacogenomic...	18 Years -	University of Chicago
Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer, Ovarian Cancer, or Squamous Cell Carcinoma of the Head and Neck	NCT00063895	Recurrent Non-s... Recurrent Ovari... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage IIIA Non-... Stage IIIA Ovar... Stage IIIB Non-... Stage IIIB Ovar... Stage IIIC Ovar... Stage IV Non-sm... Stage IV Ovaria... Stage IV Squamo... Stage IV Squamo... Stage IVA Squam... Stage IVA Squam... Stage IVA Squam... Stage IVB Squam... Stage IVB Squam... Stage IVB Squam... Stage IVC Squam... Stage IVC Squam... Stage IVC Squam...	erlotinib hydro... pharmacological... pharmacogenomic... laboratory biom...	18 Years -	National Cancer Institute (NCI)
Cyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic Syndrome	NCT00445744	Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Childhood Acute... Childhood Myelo... de Novo Myelody... Essential Throm... Myelodysplastic... Polycythemia Ve... Previously Trea... Primary Myelofi... Recurrent Adult... Recurrent Child... Secondary Acute... Secondary Myelo... Secondary Myelo... Untreated Adult... Untreated Child...	cyclophosphamid... busulfan tacrolimus methotrexate cytogenetic ana... flow cytometry pharmacological... pharmacogenomic... peripheral bloo... allogeneic hema...	- 65 Years	Fred Hutchinson Cancer Center
Sunitinib Malate and Combination Chemotherapy as Front-Line Therapy in Treating Patients With Metastatic Rectal Cancer That Cannot Be Removed by Surgery	NCT00936832	Colorectal Canc... Metastatic Canc...	FOLFIRI regimen fluorouracil irinotecan hydr... leucovorin calc... sunitinib malat... laboratory biom... pharmacogenomic... pharmacological...	18 Years - 120 Years	Federation Francophone de Cancerologie Digestive
Capecitabine and Celecoxib in Patients With Solid Cancers That Have Been Previously Treated With Standard Therapies	NCT01705106	Unspecified Adu...	capecitabine celecoxib pharmacological... laboratory biom... pharmacogenomic...	18 Years -	University of Chicago
Sorafenib Tosylate and Everolimus in Treating Patients With Advanced Solid Tumors and Metastatic Pancreatic Cancer That Does Not Respond to Gemcitabine Hydrochloride	NCT00981162	Acinar Cell Ade... Duct Cell Adeno... Recurrent Pancr... Stage IV Pancre... Unspecified Adu...	sorafenib tosyl... everolimus laboratory biom... pharmacogenomic... pharmacological...	18 Years -	Roswell Park Cancer Institute
Pralatrexate and Fluorouracil in Treating Patients With Recurrent Solid Tumors	NCT01206465	Unspecified Adu...	pralatrexate fluorouracil laboratory biom... DNA analysis high performanc... polymerase chai... nucleic acid se... pharmacological... pharmacogenomic... polymorphism an...	19 Years -	University of Nebraska
White Button Mushroom Extract in Preventing the Recurrence of Breast Cancer in Postmenopausal Breast Cancer Survivors	NCT00709020	Breast Cancer Cancer Survivor	white button mu... flow cytometry high performanc... laboratory biom... mass spectromet... pharmacogenomic... pharmacological...	21 Years -	City of Hope Medical Center
Epirubicin, Docetaxel, and Capecitabine in Treating Women With Stage IIIA or Stage IIIB Breast Cancer	NCT00645866	Breast Cancer	capecitabine docetaxel epirubicin hydr... laboratory biom... pharmacogenomic... biopsy neoadjuvant the... therapeutic sur...	18 Years -	Mayo Clinic
Gemcitabine With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer	NCT00088894	Adenocarcinoma ... Recurrent Pancr... Stage II Pancre... Stage III Pancr... Stage IV Pancre...	gemcitabine hyd... bevacizumab placebo laboratory biom... pharmacogenomic... pharmacological...	18 Years -	National Cancer Institute (NCI)
Studying Blood Samples From Women With Breast Cancer or Ductal Carcinoma In Situ Who Are Receiving Tamoxifen	NCT00764322	Breast Cancer Menopausal Symp...	tamoxifen citra... gene expression... pharmacogenomic... questionnaire a... quality-of-life...	21 Years - 120 Years	UNC Lineberger Comprehensive Cancer Center
Biomarkers in Women Receiving Chemotherapy & Celecoxib for Stage II or Stage III Breast Cancer Removable by Surgery	NCT00665457	Breast Cancer	filgrastim capecitabine celecoxib cyclophosphamid... docetaxel doxorubicin hyd... gene expression... polymorphism an... protein express... reverse transcr... imaging biomark... immunohistochem... laboratory biom... pharmacogenomic... dynamic contras... needle biopsy neoadjuvant the... radiomammograph... ultrasound imag...	19 Years - 120 Years	University of Nebraska
Study of Tissue Samples From Patients With Glioma or Other Brain Tumors	NCT00967200	Central Nervous...	laboratory biom... pharmacogenomic...	18 Years - 120 Years	University Hospital, Montpellier
Low-Dose Tamoxifen Citrate in Reducing Breast Cancer Risk in Radiation-Induced Cancer Survivors	NCT01196936	Breast Cancer	Tamoxifen Citra... Placebo Digital mammogr... immunohistochem... pharmacological... laboratory biom... protein express... pharmacogenomic... questionnaire a... Fine needle asp... Quality of Life...	25 Years -	University of Alabama at Birmingham
Abiraterone Acetate in Treating Postmenopausal Women With Advanced or Metastatic Breast Cancer	NCT00755885	Breast Cancer	abiraterone ace... laboratory biom... pharmacogenomic...	18 Years -	Cancer Research UK
S8516-S8736-S9125-S9240 Research Study of Genes in Tissue Samples From Patients With B-cell Non-Hodgkin Lymphoma	NCT00985699	Lymphoma	polymorphism an... laboratory biom... pharmacogenomic...	18 Years -	SWOG Cancer Research Network
Selumetinib and Akt Inhibitor MK-2206 in Treating Patients With Refractory or Advanced Gallbladder or Bile Duct Cancer That Cannot Be Removed By Surgery	NCT01859182	Adenocarcinoma ... Adenocarcinoma ... Adult Primary C... Advanced Adult ... Cholangiocarcin... Localized Unres... Metastatic Extr... Recurrent Adult... Recurrent Extra... Stage II Gallbl... Stage IIIA Gall... Stage IIIB Gall... Stage IVA Gallb... Stage IVB Gallb... Unresectable Ex...	selumetinib Akt inhibitor M... laboratory biom... pharmacogenomic... quality-of-life...	18 Years -	National Cancer Institute (NCI)
Breath Test for Women Receiving Tamoxifen in the Prevention or Treatment of Breast Cancer	NCT00873366	Breast Cancer	dextromethorpha... tamoxifen citra... high performanc... laboratory biom... pharmacogenomic... pharmacological... fluorescence im...	18 Years - 120 Years	Mayo Clinic
Studying Blood Samples From Women With Breast Cancer or Ductal Carcinoma In Situ Who Are Receiving Tamoxifen	NCT00764322	Breast Cancer Menopausal Symp...	tamoxifen citra... gene expression... pharmacogenomic... questionnaire a... quality-of-life...	21 Years - 120 Years	UNC Lineberger Comprehensive Cancer Center
Transarterial Chemoembolization Using Doxorubicin Beads With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery	NCT01324076	Liver Cancer	doxorubicin-elu... sorafenib tosyl... laboratory biom... pharmacogenomic... pharmacological... quality-of-life...	18 Years -	National Cancer Institute (NCI)
Erlotinib Hydrochloride and Radiation Therapy in Stage III-IV Squamous Cell Cancer of the Head and Neck	NCT01192815	Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Verru... Stage III Verru... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Verruc... Stage IV Verruc...	erlotinib hydro... intensity-modul... pharmacogenomic... gene expression... 3-dimensional c... biopsy pharmacological... laboratory biom... questionnaire a... enzyme-linked i... polymorphism an...	18 Years - 70 Years	Case Comprehensive Cancer Center
Alvespimycin Hydrochloride in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia	NCT01126502	B-cell Chronic ... Prolymphocytic ... Recurrent Small... Refractory Chro...	alvespimycin hy... diagnostic labo... pharmacogenomic... pharmacological...	18 Years -	National Cancer Institute (NCI)
Biomarkers in Women Receiving Chemotherapy & Celecoxib for Stage II or Stage III Breast Cancer Removable by Surgery	NCT00665457	Breast Cancer	filgrastim capecitabine celecoxib cyclophosphamid... docetaxel doxorubicin hyd... gene expression... polymorphism an... protein express... reverse transcr... imaging biomark... immunohistochem... laboratory biom... pharmacogenomic... dynamic contras... needle biopsy neoadjuvant the... radiomammograph... ultrasound imag...	19 Years - 120 Years	University of Nebraska
Studying Blood Samples From Women With Breast Cancer or Ductal Carcinoma In Situ Who Are Receiving Tamoxifen	NCT00764322	Breast Cancer Menopausal Symp...	tamoxifen citra... gene expression... pharmacogenomic... questionnaire a... quality-of-life...	21 Years - 120 Years	UNC Lineberger Comprehensive Cancer Center
Docetaxel, Cisplatin, Pegfilgrastim, and Erlotinib Hydrochloride in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer	NCT01557959	Adenocarcinoma ... Adenosquamous C... Bronchoalveolar... Large Cell Lung... Non-small Cell ... Recurrent Non-s... Squamous Cell L... Stage IIIB Non-... Stage IV Non-sm...	cisplatin pegfilgrastim erlotinib hydro... laboratory biom... polymorphism an... pharmacogenomic... genetic linkage... docetaxel	18 Years -	Wake Forest University Health Sciences
Saracatinib in Treating Patients With Previously Treated Metastatic Pancreatic Cancer	NCT00735917	Adenocarcinoma ... Recurrent Pancr... Stage IV Pancre...	saracatinib pharmacogenomic... pharmacological... positron emissi... fludeoxyglucose... laboratory biom...	18 Years -	National Cancer Institute (NCI)
Capecitabine and Celecoxib in Patients With Solid Cancers That Have Been Previously Treated With Standard Therapies	NCT01705106	Unspecified Adu...	capecitabine celecoxib pharmacological... laboratory biom... pharmacogenomic...	18 Years -	University of Chicago
Comparison of Chemotherapy Regimens in Treating Children With Relapsed or Progressive Rhabdomyosarcoma	NCT00025363	Alveolar Childh... Embryonal Child... Embryonal-botry... Previously Trea... Recurrent Child...	vincristine sul... irinotecan hydr... cyclophosphamid... doxorubicin hyd... ifosfamide etoposide tirapazamine filgrastim sargramostim pharmacological... pharmacogenomic... laboratory biom...	- 20 Years	National Cancer Institute (NCI)
Biomarkers in Predicting Neurotoxicity in Patients With Colorectal Cancer Receiving Oxaliplatin	NCT00884767	Chemotherapeuti... Colorectal Canc... Neurotoxicity	FOLFOX regimen fluorouracil leucovorin calc... oxaliplatin gene expression... protein express... proteomic profi... laboratory biom... pharmacogenomic...	18 Years -	National Cancer Institute (NCI)
Pazopanib Hydrochloride or a Placebo in Treating Patients With Non-Small Cell Lung Cancer Who Have Received First-Line Chemotherapy	NCT01208064	Lung Cancer	pazopanib hydro... laboratory biom... pharmacogenomic... pharmacological... quality-of-life...	18 Years - 120 Years	European Organisation for Research and Treatment of Cancer - EORTC
Irinotecan Hydrochloride, Fluorouracil, and Leucovorin Calcium With or Without Zibotentan in Treating Patients With Metastatic Colorectal Cancer	NCT01205711	Colorectal Canc...	FOLFIRI regimen fluorouracil irinotecan hydr... leucovorin calc... zibotentan laboratory biom... pharmacogenomic...	18 Years -	Cardiff University
TLR8 Agonist VTX-2337 and Cetuximab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Squamous Cell Cancer of Head and Neck	NCT01334177	Metastatic Squa... Recurrent Metas... Recurrent Saliv... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Verru... Recurrent Verru... Salivary Gland ... Stage III Saliv... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Verru... Stage III Verru... Stage IV Saliva... Stage IVA Squam... Stage IVA Squam... Stage IVA Squam... Stage IVA Squam... Stage IVA Verru... Stage IVA Verru... Stage IVB Squam... Stage IVB Squam... Stage IVB Squam... Stage IVB Squam... Stage IVB Verru... Stage IVB Verru... Stage IVC Squam... Stage IVC Squam... Stage IVC Squam... Stage IVC Squam... Stage IVC Verru... Stage IVC Verru... Tongue Cancer	TLR8 agonist VT... cetuximab laboratory biom... pharmacogenomic...	18 Years -	University of Washington
Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma	NCT01479842	Extranodal Marg... Nodal Marginal ... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Splenic Margina... Waldenstrom Mac...	BTK inhibitor P... rituximab bendamustine hy... pharmacogenomic... pharmacological... laboratory biom...	18 Years -	Ohio State University Comprehensive Cancer Center
Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer, Ovarian Cancer, or Squamous Cell Carcinoma of the Head and Neck	NCT00063895	Recurrent Non-s... Recurrent Ovari... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage IIIA Non-... Stage IIIA Ovar... Stage IIIB Non-... Stage IIIB Ovar... Stage IIIC Ovar... Stage IV Non-sm... Stage IV Ovaria... Stage IV Squamo... Stage IV Squamo... Stage IVA Squam... Stage IVA Squam... Stage IVA Squam... Stage IVB Squam... Stage IVB Squam... Stage IVB Squam... Stage IVC Squam... Stage IVC Squam... Stage IVC Squam...	erlotinib hydro... pharmacological... pharmacogenomic... laboratory biom...	18 Years -	National Cancer Institute (NCI)
Biomarkers in Predicting Neurotoxicity in Patients With Colorectal Cancer Receiving Oxaliplatin	NCT00884767	Chemotherapeuti... Colorectal Canc... Neurotoxicity	FOLFOX regimen fluorouracil leucovorin calc... oxaliplatin gene expression... protein express... proteomic profi... laboratory biom... pharmacogenomic...	18 Years -	National Cancer Institute (NCI)
Comparison of Chemotherapy Regimens in Treating Children With Relapsed or Progressive Rhabdomyosarcoma	NCT00025363	Alveolar Childh... Embryonal Child... Embryonal-botry... Previously Trea... Recurrent Child...	vincristine sul... irinotecan hydr... cyclophosphamid... doxorubicin hyd... ifosfamide etoposide tirapazamine filgrastim sargramostim pharmacological... pharmacogenomic... laboratory biom...	- 20 Years	National Cancer Institute (NCI)
Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma	NCT01479842	Extranodal Marg... Nodal Marginal ... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Splenic Margina... Waldenstrom Mac...	BTK inhibitor P... rituximab bendamustine hy... pharmacogenomic... pharmacological... laboratory biom...	18 Years -	Ohio State University Comprehensive Cancer Center
Irinotecan in Treating Asian Patients With Solid Tumors	NCT00731276	Unspecified Adu...	irinotecan hydr... pharmacogenomic... pharmacological...	21 Years - 120 Years	National Cancer Centre, Singapore
A Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS)	NCT01824836	Estrogen Recept... Musculoskeletal... Progesterone Re... Recurrent Breas... Stage IA Breast... Stage IB Breast... Stage II Breast... Stage IIIA Brea... Stage IIIB Brea... Stage IIIC Brea...	anastrozole questionnaire a... laboratory biom... pharmacogenomic...	18 Years -	Eastern Cooperative Oncology Group
Carboplatin, Gemcitabine Hydrochloride, and Stereotactic Body Radiation Therapy in Gynecological Cancer	NCT01652794	Leydig Cell Tum... Ovarian Sarcoma Ovarian Stromal... Pseudomyxoma Pe... Recurrent Cervi... Recurrent Endom... Recurrent Fallo... Recurrent Ovari... Recurrent Ovari... Recurrent Prima... Recurrent Uteri... Recurrent Vagin... Recurrent Vulva...	stereotactic bo... carboplatin gemcitabine hyd... laboratory biom... pharmacogenomic...	19 Years -	Case Comprehensive Cancer Center
Low-Dose Tamoxifen Citrate in Reducing Breast Cancer Risk in Radiation-Induced Cancer Survivors	NCT01196936	Breast Cancer	Tamoxifen Citra... Placebo Digital mammogr... immunohistochem... pharmacological... laboratory biom... protein express... pharmacogenomic... questionnaire a... Fine needle asp... Quality of Life...	25 Years -	University of Alabama at Birmingham

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: